Adams SR et al. |
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. |
2016 |
Nat Commun |
pmid:27698471
|
Mahtani RL and Vogel CL |
When Can a Salvage Therapy (T-DM1) Take the Lead? |
2016 |
J. Clin. Oncol. |
pmid:27432926
|
Le QA et al. |
Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. |
2016 |
Breast Cancer Res. Treat. |
pmid:27572338
|
Eckelmann D et al. |
Occurrence and spatial distribution of maytansinoids in Putterlickia pyracantha, an unexplored resource of anticancer compounds. |
2016 |
Fitoterapia |
pmid:27521896
|
Chen Y et al. |
Structural Characterization of Cross-Linked Species in Trastuzumab Emtansine (Kadcyla). |
2016 |
Bioconjug. Chem. |
pmid:27458087
|
Li C et al. |
Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. |
2016 |
Cancer Chemother. Pharmacol. |
pmid:27423671
|
Chen L et al. |
In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. |
2016 |
MAbs |
pmid:27380163
|
Géraud A et al. |
Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. |
2016 |
Cancer Radiother |
pmid:27342941
|
Fan Y et al. |
Enhancement of UDPG synthetic pathway improves ansamitocin production in Actinosynnem pretiosum. |
2016 |
Appl. Microbiol. Biotechnol. |
pmid:26585444
|
Li S et al. |
Constitutive overexpression of asm18 increases the production and diversity of maytansinoids in Actinosynnema pretiosum. |
2016 |
Appl. Microbiol. Biotechnol. |
pmid:26572523
|
Roviello G et al. |
Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. |
2016 |
Tumour Biol. |
pmid:26566626
|
Zhang YG et al. |
Nocardiopsis ansamitocini sp. nov., a new producer of ansamitocin P-3 of the genus Nocardiopsis. |
2016 |
Int. J. Syst. Evol. Microbiol. |
pmid:26486850
|
Cilliers C et al. |
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. |
2016 |
AAPS J |
pmid:27287046
|
Martin M and López-Tarruella S |
Emerging Therapeutic Options for HER2-Positive Breast Cancer. |
2016 |
Am Soc Clin Oncol Educ Book |
pmid:27249772
|
Singh R et al. |
A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. |
2016 |
Mol. Cancer Ther. |
pmid:27197308
|
Bellat V et al. |
Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties. |
2016 |
Biomacromolecules |
pmid:27180972
|
Ogitani Y et al. |
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. |
2016 |
Cancer Sci. |
pmid:27166974
|
Feng L et al. |
Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. |
2016 |
J. Exp. Clin. Cancer Res. |
pmid:27102688
|
|
T-DM1 Combo Graduates from I-SPY 2. |
2016 |
Cancer Discov |
pmid:27095360
|
Singh AP et al. |
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). |
2016 |
AAPS J |
pmid:27029797
|